Literature DB >> 28647698

Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival.

Catherine Zabkiewicz1, Jeyna Resaul1, Rachel Hargest1, Wen Guo Jiang2, Lin Ye2.   

Abstract

BACKGROUND/AIM: Activin and its antagonist follistatin (FST) have been implicated in several solid tumours. This study investigated the role of FST in breast cancer.
MATERIALS AND METHODS: FST expression was examined using reverse transcription polymerase chain reaction (RT-PCR), real-time quantitative polymerase chain reaction (qPCR) and immunohistochemistry in a cohort of breast cancer samples. Expression was correlated to pathological and prognostic parameters in our patient cohort. FST was overexpressed in MCF-7 cells and assays for growth and invasion were performed.
RESULTS: FST is expressed in breast tissue, in the cytoplasm of mammary epithelial cells. Expression was decreased in breast cancer tissue in comparison to normal mammary tissue. Over-expression of FST in vitro led to significantly increased growth rate and reduced invasion. Higher FST associates with lower-grade tumours and better survival.
CONCLUSION: Our results suggest a role for FST as a suppressor of invasion and metastasis in breast cancer. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Follistatin; breast cancer; survival

Mesh:

Substances:

Year:  2017        PMID: 28647698      PMCID: PMC5572302          DOI: 10.21873/cgp.20035

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  33 in total

1.  Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells.

Authors:  Joanna E Burdette; Jacqueline S Jeruss; Sarah J Kurley; Eun Jig Lee; Teresa K Woodruff
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

Review 2.  The bright and the dark sides of activin in wound healing and cancer.

Authors:  Maria Antsiferova; Sabine Werner
Journal:  J Cell Sci       Date:  2012-09-18       Impact factor: 5.285

Review 3.  Antagonists of activin signaling: mechanisms and potential biological applications.

Authors:  Craig A Harrison; Peter C Gray; Wylie W Vale; David M Robertson
Journal:  Trends Endocrinol Metab       Date:  2005-03       Impact factor: 12.015

4.  Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors.

Authors:  Jelena Krneta; Jens Kroll; Frauke Alves; Claudia Prahst; Farahnaz Sananbenesi; Christian Dullin; Sarah Kimmina; David J Phillips; Hellmut G Augustin
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

5.  Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay.

Authors:  Alan L Schneyer; Qifa Wang; Yisrael Sidis; Patrick M Sluss
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

6.  Follistatin antagonizes transforming growth factor-beta3-induced epithelial-mesenchymal transition in vitro: implications for murine palatal development supported by microarray analysis.

Authors:  Hendrik Nogai; Mark Rosowski; Joachim Grün; Anika Rietz; Nils Debus; Gül Schmidt; Carola Lauster; Michal Janitz; Andrea Vortkamp; Roland Lauster
Journal:  Differentiation       Date:  2007-11-20       Impact factor: 3.880

7.  Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice.

Authors:  Hirokazu Ogino; Seiji Yano; Soji Kakiuchi; Hiroaki Muguruma; Kenji Ikuta; Masaki Hanibuchi; Hisanori Uehara; Kunihiro Tsuchida; Hiromu Sugino; Saburo Sone
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

8.  The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.

Authors:  Caroline Wilson; Penelope Ottewell; Robert E Coleman; Ingunn Holen
Journal:  BMC Cancer       Date:  2015-02-14       Impact factor: 4.430

9.  Differential expression of follistatin and FLRG in human breast proliferative disorders.

Authors:  Enrrico Bloise; Henrique L Couto; Lauretta Massai; Pasquapina Ciarmela; Marzia Mencarelli; Lavinia E Borges; Michela Muscettola; Giovanni Grasso; Vania F Amaral; Geovanni D Cassali; Felice Petraglia; Fernando M Reis
Journal:  BMC Cancer       Date:  2009-09-09       Impact factor: 4.430

Review 10.  Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer.

Authors:  Denise A Yardley
Journal:  Breast Cancer (Dove Med Press)       Date:  2016-05-03
View more
  5 in total

1.  Human organotypic lymphatic vessel model elucidates microenvironment-dependent signaling and barrier function.

Authors:  Max M Gong; Karina M Lugo-Cintron; Bridget R White; Sheena C Kerr; Paul M Harari; David J Beebe
Journal:  Biomaterials       Date:  2019-05-25       Impact factor: 12.479

Review 2.  The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer.

Authors:  Darcie D Seachrist; Ruth A Keri
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

3.  Global DNA Methylation Profiles in Peripheral Blood of WTC-Exposed Community Members with Breast Cancer.

Authors:  Stephanie Tuminello; Yian Zhang; Lei Yang; Nedim Durmus; Matija Snuderl; Adriana Heguy; Anne Zeleniuch-Jacquotte; Yu Chen; Yongzhao Shao; Joan Reibman; Alan A Arslan
Journal:  Int J Environ Res Public Health       Date:  2022-04-22       Impact factor: 4.614

4.  Systematic interrogation of mutation groupings reveals divergent downstream expression programs within key cancer genes.

Authors:  Michal R Grzadkowski; Hannah D Holly; Julia Somers; Emek Demir
Journal:  BMC Bioinformatics       Date:  2021-05-06       Impact factor: 3.307

5.  Association of serum follistatin levels with histological types and progression of tumor in human lung cancer.

Authors:  Pengyu Zhang; Yingxin Ruan; Jun Xiao; Fangfang Chen; Xuejun Zhang
Journal:  Cancer Cell Int       Date:  2018-10-20       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.